Mid‐trimester termination for fetal abnormality: advantages of a new regimen using mifepristone and misoprostol

BJOG: An International Journal of Obstetrics & Gynaecology

Volumn 102, Issue 7, 1995, Pages 559-560

  Hinshaw, Kim ^a   El‐Refaey, Hazem ^a   Rispin, Rachel ^a   Templeton, Allan ^a  

^a ABERDEEN MATERNITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; MISOPROSTOL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FETUS DISEASE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PREGNANCY TERMINATION; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; FEMALE; FETUS; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; PREGNANCY TRIMESTER, SECOND;

EID: 0028997386     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1995.tb11361.x     Document Type: Article

References (8)

1. Medical abortion in Britain
2. The abortifacient effect of misoprostol in the second trimester. A randomised comparison with gemeprost in patients pre‐treated with mifepristone (RU486)
3. Early pregnancy termination induced by a combination of mifepristone and vaginal misoprostol
4. The loss of early pregnancy
5. The impact of midtrimester abortion techniques on patients and staff
6. Medical management of abnormal pregnancy
7. Pretreatment with mifepristone (RU486) reduces the interval between prostaglandin administration and expulsion in second trimester abortion